Publicacions en què col·labora amb FRANCISCO JAVIER CUBERO PALERO (39)

2024

  1. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

    JHEP Reports, Vol. 6, Núm. 1

  2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)

    Gut Microbes, Vol. 16, Núm. 1

2023

  1. Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming

    Journal of Hepatology, Vol. 79, Núm. 3, pp. 728-740

  2. Lack of Cyclin E1 in hepatocytes aggravates ethanol-induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

  3. Neuroblastoma RAS viral oncogene homolog (N-RAS) deficiency aggravates liver injury and fibrosis

    Cell death & disease, Vol. 14, Núm. 8, pp. 514

  4. Novel therapeutic avenues for the study of chronic liver disease and regeneration: The foundation of the Iberoamerican Consortium for the study of liver Cirrhosis

    Gastroenterologia y Hepatologia

  5. Obesity under the moonlight of c-MYC

    Frontiers in Cell and Developmental Biology, Vol. 11

  6. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

  7. Tumor progression locus 2 (TPL2): A Cot-plicated progression from inflammation to chronic liver disease

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1869, Núm. 4

2022

  1. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy

    Cancers, Vol. 14, Núm. 1

  2. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  3. Genetic and pharmacological inhibition of XBP1 protects against APAP hepatotoxicity through the activation of autophagy

    Cell death & disease, Vol. 13, Núm. 2, pp. 143

  4. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

2021

  1. Abnormal liver function test in patients infected with coronavirus (Sars-cov-2): A retrospective single-center study from spain

    Journal of Clinical Medicine, Vol. 10, Núm. 5, pp. 1-18

  2. An Experimental DUAL Model of Advanced Liver Damage

    Hepatology Communications, Vol. 5, Núm. 6, pp. 1051-1068

  3. Fat: Quality, or quantity? what matters most for the progression of metabolic associated fatty liver disease (mafld)

    Biomedicines, Vol. 9, Núm. 10

  4. Fibrotic events in the progression of cholestatic liver disease

    Cells, Vol. 10, Núm. 5

  5. Gender and gut microbiota composition determine hepatic bile acid, metabolic and inflammatory response to a single fast-food meal in healthy adults

    Clinical Nutrition, Vol. 40, Núm. 5, pp. 2609-2619

  6. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19

    Digestive and Liver Disease, Vol. 53, Núm. 5, pp. 525-533

  7. The Space of Disse: The Liver Hub in Health and Disease

    Livers, Vol. 1, Núm. 1, pp. 3-26